Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 4 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 4 25 IN PLASTIC CONTAINER.
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER vs INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dialysis solution containing dextrose and electrolytes; dextrose provides osmotic gradient for ultrafiltration and caloric supplementation, while electrolytes maintain acid-base and electrolyte balance in peritoneal dialysis.
Removes uremic toxins and excess fluid via diffusion and ultrafiltration across the peritoneal membrane.
Intravenous infusion, 500-2000 mL per day as maintenance fluid; rate adjusted based on clinical status, typically 1-2 mL/kg/hour in adults.
Intraperitoneal: For continuous ambulatory peritoneal dialysis (CAPD), instill 2 liters of 4.25% dextrose solution into the peritoneal cavity four times daily (4 exchanges/day). For automated peritoneal dialysis (APD), use 2-3 liters per cycle with multiple cycles overnight. Adjust volume and frequency based on patient's fluid and electrolyte status.
None Documented
None Documented
Terminal half-life: 2.5–3.5 hours. Clinically, this allows for rapid clearance; accumulation may occur in renal impairment.
Dextrose: approximately 1-2 hours (terminal half-life of glucose in plasma); clinical context: continuous peritoneal dialysis (CAPD) maintains steady-state glucose levels.
Renal: >95% as unchanged drug and metabolites. Biliary/fecal: <5%.
Renal: 80-90% of dextrose metabolites (CO2 and H2O) are excreted via lungs and kidneys; electrolytes and water are eliminated renally. Biliary/fecal: minimal (<5%).
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution